ERN-EuroBloodNet Registry on Patients With Rare Red Blood Cell Defects and COVID-19

Key facts

Sponsor

Hospital Universitari Vall d'Hebron Research Institute

Principal Investigator

María del Mar Mañú Pereira, PhD

Vall d'Hebron Institut de Recerca, Barcelona (Spain) and ERN-EuroBloodNet

Intervention

Non applicable, is a patient registry(other)

Enrollment

684 enrolled

Eligibility

All sexes

Timeline

2020 – 2023

Study locations (1)

• Vall d'Hebron Institut de Recerca, Barcelona, Barcelona, Spain

Collaborators

European Georges Pompidou Hospital · Hospital General Universitario Gregorio Marañon · Hospital Vall d'Hebron · Unidade Local de Saúde de Coimbra, EPE · University Hospital Freiburg · Azienda Ospedaliera di Padova · Hôpital Necker-Enfants Malades · Guy's and St Thomas' NHS Foundation Trust · Erasme University Hospital · Aghia Sophia Children's Hospital of Athens · Cyprus Institute of Neurology and Genetics · University Hospital Heidelberg · Children's Health Ireland · San Luigi Gonzaga Hospital · Oxford University Hospitals NHS Trust · UMC Utrecht · General Hospital of Athens Elpis · Amsterdam UMC · Brno University Hospital · Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello · University Hospital, Gentofte, Copenhagen · Institute of Hematology and Blood Transfusion, Czech Republic · Universitaire Ziekenhuizen KU Leuven · Palacky University

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Alpha-thalassemia

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT06591936
  Genetic Profile of Alpha Thalassemia Children at Sohag University Hospital .
  Sohag University
• RECRUITINGNANCT06539169
  FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases
  xCures
• RECRUITINGEARLY PHASE1NCT06107400
  Safety and Efficacy of RM-004 Cells for Hemoglobin H-Constant Spring Disease
  The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army
• RECRUITINGPHASE2NCT05664737
  A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-Thalassemia
  Bristol-Myers Squibb
• ACTIVE NOT RECRUITINGPHASE3NCT04770753
  A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)
  Agios Pharmaceuticals, Inc.
• ACTIVE NOT RECRUITINGPHASE3NCT04770779
  A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)
  Agios Pharmaceuticals, Inc.
• ACTIVE NOT RECRUITINGNANCT02692872
  Screening for Alpha Thalassemia in Healthy Volunteers
  National Institute of Allergy and Infectious Diseases (NIAID)
• RECRUITINGNCT04872179
  International Registry of Patients With Alpha Thalassemia
  University of California, San Francisco

See all trials for Alpha-thalassemia →